NVDA
52
-4
NWSA
73
2
EXC
67
-2
EXPE
78
-2
HRB
50
-2
PCG
62
-2
KIM
61
-3
CL
48
-2
PNW
64
-3
HBI
59
-5
IP
67
10
DNB
60
-2
DIS
72
3
CVS
53
-3
GM
72
6
MCHP
42
-4
FTI
68
5
HSY
32
-2
FE
45
-7
CNP
68
-3
NVDA
52
-4
NWSA
73
2
EXC
67
-2
EXPE
78
-2
HRB
50
-2
PCG
62
-2
KIM
61
-3
CL
48
-2
PNW
64
-3
HBI
59
-5
IP
67
10
DNB
60
-2
DIS
72
3
CVS
53
-3
GM
72
6
MCHP
42
-4
FTI
68
5
HSY
32
-2
FE
45
-7
CNP
68
-3
Financhill
Back

Purple Innovation 10K Form

Sell
27

PRPL
Purple Innovation

Last Price:
$0.80
Seasonality Move:
20.86%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive PRPL News And Ratings

See the #1 stock for the next 7 days that we like better than PRPL

PRPL Financial Statistics

Sales & Book Value

Annual Sales: $487.9M
Cash Flow: $5.6M
Price / Cash Flow: 0
Annual Sales: $0.19
Price / Book: 4.28

Profitability

EPS (TTM): -0.91010
Net Income (TTM): $-97.9M
Gross Margin: $181.1M
Return on Equity: -165.32%
Return on Assets: -27.94%

Purple Innovation Earnings Forecast

Key Purple Innovation Financial Ratios

  • The Gross Profit Margin over the past 8 years for PRPL is 37.13%.
  • The Selling, General & Administrative Expenses for PRPL have been equal to 49.27% of Gross Profit Margin.
  • The Research & Development expenses have been 2.66% of Revenue.
  • The Net Earning history of PRPL is -20.07% of Total Revenues.
  • Per Share Earnings over the last 10 years have been positive in 3 years.

Purple Innovation Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Household Durables
Sector: Consumer Discretionary
Current Symbol: PRPL
CUSIP: 74640Y
Website: purple.com

Debt

Debt-to-Equity Ratio: 2.74
Current Ratio: 1.25
Quick Ratio: 0.61

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

PRPL Technical Analysis vs Fundamental Analysis

Sell
27
Purple Innovation (PRPL) is a Sell

Is Purple Innovation a Buy or a Sell?

  • Purple Innovation stock is rated a Sell
    The current Purple Innovation [PRPL] share price is $0.79. The Score for PRPL is 27, which is 46% below its historic median score of 50, and infers higher risk than normal.